Cargando…
Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...
Autores principales: | Nishio, Eiji, Hayashi, Takanori, Akaza, Mao, Hisatomi, Yukiko, Hikichi, Masahiro, Fujii, Takuma, Utsumi, Toshiaki, Harada, Nobuhiro, Shimono, Yohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530388/ https://www.ncbi.nlm.nih.gov/pubmed/32810922 http://dx.doi.org/10.1002/2211-5463.12956 |
Ejemplares similares
-
Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
por: Hayashi, Takanori, et al.
Publicado: (2018) -
Lack of association of ovariectomy-induced obesity with overeating and the reduction of physical activities
por: Nishio, Eiji, et al.
Publicado: (2019) -
Asian trends in primary androgen depletion therapy on prostate cancer
por: Akaza, Hideyuki
Publicado: (2013) -
Transcriptional regulation of CYP19 by cohesin-mediated chromosome tethering in human granulosa cells
por: Kotomura, Naoe, et al.
Publicado: (2021) -
Rare recurrence of a multilocular cystic leiomyoma following myomectomy
por: Nishio, Eiji, et al.
Publicado: (2023)